Publications
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived
FKBPL: a marker of good prognosis in breast cancer. Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirstrom K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Oncotarget 2015;6(14):12209-23.
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, Morgan DA, Martin SG. Oncotarget. 2014 Dec 30;5(24):12936-49.
MIR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. EM Nilsson, KB Laursen, J Whitchurch, A McWilliam, N Odum, JL Persson, DM Heery, LJ Gudas and NP Mongan. (2015) Oncotarget 1-16.
Novel Motifs Mediate Selective Interactions of BCL11A with the COUPTF, Tailless and PNR Subfamily of Orphan. CM Chan, J Fulton, C Montiel Duarte, HM Collins, F Wadelin, N Bharti, PM Moran, NP Mongan &, DM Heery. (2013) Nucleic Acids Research 2013 Aug 23. [Epub ahead of print] PMID: 23975195.
The Double PHD Finger Domain of MOZ/MYST3 Induces -Helical Structure of the Histone H3 Tail to Facilitate Acetylation and Methylation Sampling and Modification. Dreveney I, Deeves SD, Yue B, Messmer M, Collins HM & Heery DM. (2013) Nucleic Acids Research (In Press) *** Breakthrough Article (Top 2%).
The shaping and functional consequences of the microRNA landscape in breast cancer. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C. Nature. doi: 10.1038/nature12108. 2013 May 5.
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF, Kell J, Wheatley K, Yin JAL, Hunter A, Milligan D, Russell NH on behalf of the United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup. Leukemia 2013 27: 843-851; advance online publication, 10.1038/leu.2012.360. 2012 December 10.
PRAME Is a Golgi-Targeted Protein that Associates with the Elongin BC Complex and Is Upregulatd by Interferon-Gamma and Bacterial PAMPs. Wadelin FR, Fulton J, Collins HM, Tertipis N, Bottley A, Spriggs KA, Falcone FH, Heery DM. PLoS ONE. 8(2): e58052. doi:10.1371/journal.pone.0058052.
Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. Collins HM, Abdelghany MK, Messmer M, Yue B, Deeves SE, Kindle KB, Mantelingu K, Aslam A, Winkler GS, Kundu TK, Heery DM. BMC Cancer. 13(1):37. 2013 Jan 29.
Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C, Ball G, Chan S, Rakha EA, Ellis IO, Madhusudan S. Cancer Res. 2013 Feb 22. [Epub ahead of print]
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. Nature. 481(7381):389-93. 2012 Jan 4.
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Oncotarget. 1(7):628-38. 2010 November.
Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Albasri A, Al-Ghamdi S, Fadhil W, Aleskandarany M, Liao YC, Jackson D, Lobo DN, Lo SH, Kumari R, Durrant L, Watson S, Kindle KB, Ilyas M. Oncogene. 30(26):2997-3002. 2011 Jun 30.
Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. Al-Ghamdi S, Albasri A, Cachat J, Ibrahem S, Muhammad BA, Jackson D, Nateri AS, Kindle KB, Ilyas M. PLoS One. 6(6):e20919. Epub 2011 Jun 16.
Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J, Ellison DW, Gilbertson RJ, Coyle B, Grill J, Grundy RG. Clin Cancer Res. 18(7):2001-11. 2012 Apr 1.
The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM. Br J Cancer. 106(7):1306-13. 2012 Mar 27.
A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turajlic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Henri Stern M, Reis-Filho JS. J Pathol. 227(1):29-41. 2012 May.
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, Jandke A, Muhammad B, Ibrahim EE, Muraleedharan R, Abuzinadah M, Davis H, Lewis A, Watson S, Behrens A, Tomlinson I, Nateri AS. J Exp Med. 2011 Feb 14;208(2):295-312. Epub 2011 Jan 31.
Epigenetic reprogramming of breast cancer cells with oocyte extracts. Allegrucci C, Rushton MD, Dixon JE, Sottile V, Shah M, Kumari R, Watson S, Alberio R, Johnson AD. Mol Cancer. 2011 Jan 13;10(1):7.
Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Mohammed MZ, Vyjayanti VN, Laughton CA, Dekker LV, Fischer PM, Wilson DM 3rd, Abbotts R, Shah S, Patel PM, Hickson ID, Madhusudan S. Br J Cancer. 2011 Feb 15;104(4):653-63.
Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance. Jeyapalan JN, Noor DA, Lee SH, Tan CL, Appleby VA, Kilday JP, Palmer RD, Schwalbe EC, Clifford SC, Walker DA, Murray MJ, Coleman N, Nicholson JC, Scotting PJ. Br J Cancer. 2011 Aug 9;105(4):575-85.
Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro. Barrett RM, Colnaghi R, Wheatley SP. Cell Cycle. 2011 Feb 1;10(3):538-48.
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair. Zhang J, Stevens MF, Hummersone M, Madhusudan S, Laughton CA, Bradshaw TD. Oncology. 2011;80(3-4):195-207.
Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Walker AJ, Grainge MJ, Card TR. Br J Cancer. 2012 Sep 25. doi: 10.1038/bjc.2012.427. [Epub ahead of print] PubMed PMID: 23011483.
Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Walker AJ, Card T, Bates TE, Muir K. Br J Cancer. 2011 Jan 4;104(1):193-7. Epub 2010 Nov 16. PubMed PMID: 21081933; PubMed Central PMCID: PMC3039809.
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. van Staa TP, Card T, Logan RF, Leufkens HG. Gut. 2005 Nov;54(11):1573-8. Epub 2005 Jun 30. Review. PubMed PMID: 15994215; PubMed Central PMCID: PMC1774734.
Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling. C. Yan, D. Siegel, J. Newsome, A. Chilloux, C. J. Moody and D. Ross, Mol. Pharm., 2012, 81, 401-410.
Biomimetic synthesis of the apoptosis-inducing thiazinoquinone thiaplidiaquinone A. A. Carbone, C. L. Lucas and C. J. Moody, J. Org. Chem., 2012, 77, 9179-9189 .
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 Trial. Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF, Kell J, Wheatley K, Yin JA, Hunter A, Milligan D, Russell NH. Leukemia. 2012 Dec 10. doi: 10.1038/leu.2012.360. [Epub ahead of print]
Improving outcomes for elderly patients with AML. Russell NH. Lancet Oncol. 2012 Nov;13(11):1065-6. doi: 10.1016/S1470-2045(12)70450-3
Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia. Jawad M, Yu N, Seedhouse C, Tandon K, Russell NH, Pallis M. BMC Cancer. 2012 Sep 26;12:431. doi: 10.1186/1471-2407-12-431.
Plerixafor and G-CSF for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Russell N, Douglas K, Ho A, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen DJ, Willemsen A, Whitaker N, Chabannon C. Haematologica. 2012 Sep 14. [Epub ahead of print]
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ. Nat Rev Clin Oncol. 2012 Oct;9(10):579-90. doi: 10.1038/nrclinonc.2012.150. Epub 2012 Sep 4.
The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. Br J Haematol. 2012 Oct;159(2):191-203. doi: 10.1111/bjh.12018. Epub 2012 Aug 30.
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30.
Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Miftakhova R, Hedblom A, Semenas J, Robinson BD, Simoulis A, Malm J, Rizvanov A, David Heery D, Mongan NP, Maitland NJ, Allegrucci C, Persson JL. Cancer Res. 2016 Feb 26. pii: canres.2340.2015. [Epub ahead of print] PMID: 26921336.
Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity. Chua JX, Vankemmelbeke M, McIntosh RS, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S, Durrant LG. Clin Cancer Res. 2015 Jul 1;21(13):2963-74. doi: 10.1158/1078-0432.CCR-14-3030. Epub 2015 Mar 16. PubMed PMID: 25779947.
Post-transcriptional control of tumor cell autonomous metastatic potential by the CCR4-NOT deadenylase CNOT7. Faraji, F., Hu, Y., Winkler, G.S., Hafner, M., and Hunter, K.W. (2016) PLoS Genetics 12, e1005820.
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived